Tessera Therapeutics was founded in 2018 by Jake Rubens and Geoffrey von Maltzahn. Tessera Therapeutics has not officially endorsed a plan to participate in an IPO.
Tessera is a biotech company developing gene editing technology to fight disease. Per Forge data, Tessera Therapeutics has raised a total of $531.8 million in funding over 3 rounds. Their latest funding was raised on Apr 19, 2022, from a Series C round. Key investors include Alaska Permanent Fund and SoftBank Vision Fund.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/19/2022 | Series C | $300MM | $xx.xx | $1.77B | Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, Salt Fund, Softbank, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
14,669,927
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset Management, Flagship Pioneering, Hanwha Impact Partners, Longevity Vision Fund, March Capital, Salt Fund, Softbank, T. Rowe Price
|
||||||
01/12/2021 | Series B | $232.5MM | $xx.xx | $760.65MM | Alaska Permanent Fund, Altitude Life Science Ventures, Qatar Investment Authority, Softbank | |
Price per Share
$xx.xx
Shares Outstanding
19,804,092
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alaska Permanent Fund, Altitude Life Science Ventures, Qatar Investment Authority, Softbank
|
||||||
07/07/2020 | Series A-2 | $5MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
2,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
07/07/2020 | Series A-1 | $6.6MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
3,298,161
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|
||||||
07/07/2020 | Series A | $14.81MM | $xx.xx | $66.08MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
14,809,929
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|